Application of ethanolamine in preparation of product for preventing, relieving and/or treating neuroinflammation-related diseases

A technology of neuroinflammation and ethanolamine, which is applied in the field of medicine, can solve the problems that the effect cannot meet the ideal expectation, and achieve the effect of reducing the level of retinal inflammation, activation and expression of inflammatory factors

Pending Publication Date: 2022-03-01
SHANGHAI FIRST PEOPLES HOSPITAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Taking diabetic retinopathy as an example, the most common treatment methods include various anti-VEGF injections (such as ranibizumab, conbercept, etc.), hormones (such as sustained-release dexamethasone injections, triamcinolone acetonide, fluocinolone, etc.) ), laser photocoagulation and vitrectomy, etc., but there are still some patients who cannot achieve the desired effect of the above treatment measures in clinical practice

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ethanolamine in preparation of product for preventing, relieving and/or treating neuroinflammation-related diseases
  • Application of ethanolamine in preparation of product for preventing, relieving and/or treating neuroinflammation-related diseases
  • Application of ethanolamine in preparation of product for preventing, relieving and/or treating neuroinflammation-related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Ethanolamine inhibits the inflammatory response of hypoxia-induced microglial cells

[0034] 1. Experimental method

[0035] In this experiment, hypoxia-induced BV2 cells were used as an in vitro model to verify the effect of ethanolamine on microglia by detecting the expression of inflammatory factors. The specific experimental process is:

[0036] Inoculate BV2 cells in a 6-well plate, add 10% FBS and penicillin / streptomycin double antibody high sugar (containing 4.5g / L glucose) DMEM medium (catalogue number 10-013-CV; Corning) for routine culture; When the cells grew to about 70%, different concentrations of ethanolamine ((catalogue number: S6210; SELLCK)) were added under hypoxic conditions to continue culturing, while a group of cells without ethanolamine but cultured under conventional conditions were kept as a control; cells were collected after 24 hours and RNA was extracted, and the expressions of related inflammatory factors were detected by qRT-PC...

Embodiment 2

[0039] Example 2 Ethanolamine inhibits hypoxia-induced NF-κB nuclear translocation in microglial cells

[0040] 1. Experimental method

[0041]NF-κB plays a key role in DR inflammatory response. Hypoxic stimulation of BV2 cells promotes inflammatory response through activation of NF-κB pathway. In order to further characterize the molecular mechanism of Ethanolamine's inhibition of inflammatory response, we detected the translocation of NF-κBp65, which is a marker of NF-κB activation. The specific experimental process is:

[0042] Discard the culture medium after hypoxia induction of BV2 cells, add 4% paraformaldehyde to fix at room temperature for 15 minutes, and permeabilize with 0.1% Triton X-100 at room temperature for 10 minutes; cells are blocked with 5% goat serum for 1 hour at room temperature , and then incubated overnight at 4°C with rabbit anti-NF-κBp65 antibody; after washing 3 times with PBS, anti-rabbit secondary IgG (1:500; Thermo Fisher Scientific, A-11008) c...

Embodiment 3

[0045] Example 3 Ethanolamine reduces the activation of retinal microglial cells in diabetic rats

[0046] 1. Experimental method

[0047] All animal experiments were performed in accordance with the ARVO Statement on the Use of Animals in Ophthalmic and Vision Research and in compliance with the guidelines required by the Ethics Committee of Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, China.

[0048] (1) Modeling treatment of diabetic rats

[0049] Male Sprague Dawley rats with a body weight of 120-160 g were randomly assigned to the diabetes group and the control group. Diabetic group rats: intraperitoneally inject streptozotocin (STZ, solvent is citrate buffer, 60 mg / kg body weight) after fasting for 24 hours; control group rats: inject the same volume of citrate buffer. Animals in the STZ model group were diagnosed as diabetic when their blood sugar exceeded 13.9mmol / L (250mg / dL) for 3 consecutive days.

[0050] (2) ethanolamine administr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of ethanolamine in preparation of products for preventing, relieving and / or treating neuroinflammation-related diseases, and relates to the field of medicines. The neuroinflammation is caused by excessive activation of microglial cells, and the neuroinflammation related diseases comprise ophthalmic diseases and central nervous system diseases. The inhibition effect of ethanolamine on microglial cell activation is evaluated through a series of experiments, and the result shows that ethanolamine can significantly relieve microglial cell activation and inflammatory factor expression by inhibiting an NF-kappa B pathway, so that the inflammation level is reduced. Therefore, when ethanolamine is applied to pharmacy or health care products and the like, products suitable for preventing, relieving and treating neuroinflammation related diseases can be obtained.

Description

technical field [0001] The invention belongs to the field of medicine and relates to the new application of ethanolamine, in particular to the application of ethanolamine in the preparation of products for preventing, alleviating and / or treating diseases related to neuroinflammation. Background technique [0002] Dysregulation of the inflammatory response can lead to tissue and organ damage, thereby promoting the development of the disease. The inflammatory response of the nervous system, or "neuroinflammation", has its own unique features and is present in neurodegenerative diseases of the central nervous system, including multiple sclerosis (MS), Parkinson's disease (PD), muscular atrophy Lateral sclerosis (ALS), Huntington's disease (HD), etc., and eye diseases such as optic nerve damage, diabetic retinopathy (DR) and glaucoma, etc. Among related diseases, these diseases are characterized by progressive neuronal dysfunction, although the pathogenesis varies, such as stro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/133A61P25/00A61P29/00A61P27/02A61P27/06A61P25/14A61P25/16A61P37/02A23L33/00
CPCA61K31/133A61P25/00A61P29/00A61P27/02A61P27/06A61P25/14A61P25/16A61P37/02A23L33/00A23V2002/00A23V2200/322
Inventor 张芳胡光奕吕康甲王育璠许迅
Owner SHANGHAI FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products